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General materials and methods
Synthesis Unless otherwise noted, solvents and reagents for synthesis were reagent grade from commercial suppliers and used without further purification. Dry CH2Cl2 and MeCN were obtained using anhydrous alumina columns. 1 All moisture-sensitive reactions were performed under a nitrogen or argon atmosphere using oven-dried glassware. Reactions were monitored by TLC on Kieselgel 60 F254 plates with detection by UV, potassium permanganate, and phosphomolybdic acid stains. Flash column chromatography was carried out using silica gel (particle size 40-63 μm). 1 (dimethylamino)propane-1,2-diyl dioleate (6). [2] [3] [4] DODEG4 was synthesised as previously described 5 as was DOSEG3 6 . 11-Bromo-3,6,9-trioxoundecan-1-ol (5), 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 5-bromopentanoate (8), and 2-(2-(2-methoxyethoxy)ethoxy)ethyl 5-bromopentanoate (9) were prepared as previously described. 5, 6 Peptide A and H-(Lys)16-OH (K16) were synthesized as previously reported. plasmid (pDNA) was supplied from Aldevron, USA. Calf thymus DNA (ctDNA) and all other cell culture media were supplied from Sigma, Poole, UK. All reagents for transfection and biophysical studies were used without further purification and were of the highest grade possible. De-ionised double distilled water was used throughout. D2O (> 99.9% D) was purchased from Aldrich, Poole, UK.
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Synthetic procedures 1-(2-Bromoethoxy)-2-(2-methoxyethoxy)ethane.
To a solution of triethylene glycol monomethyl ether (3.0 mL, 19 mmol) in dichloromethane (50 mL) at 0 °C, thionyl bromide (2.0 mL, 26 mmol mmol) was added dropwise. The reaction was stirred at room temperature for 18 h, the organic phase washed with water (2 × 50 mL), dried (MgSO4) and concentrated in vacuo. The crude product was purified by flash silica chromatography (hexane/Et2O, 
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pale yellow oil (249 mg, 78%). RF 0.32 (CH2Cl2/MeOH, 9:1); nmax(neat)/cm 
2-(2-(2-(Bromoethoxy)ethoxy)ethoxy)ethyl acetate 10.
To a solution of 5 (1.00 g, 3.89 mmol) and 4-dimethylaminopyridine (0.095 g, 0.78 mmol) in pyridine (10 mL) acetic anhydride (0.80 g, 7.8 mmol) was added dropwise. The reaction was then heated at 60 °C for 4 h and the pyridine was removed in vacuo. Dichloromethane (10 mL) was added, and the solution was washed with HCl (1 M; 100 mL), saturated NaHCO3 (100 mL), and brine (100 mL), dried N-(2,3-Bis(oleoyloxy)propyl)-N,N-dimethyl-13-oxo-3,6,9 ,12-tetraoxatetradecan-1-aminium bromide AC-DOesDEG4.
A solution of the amine 6 3 (0.194 g, 0.300 mmol) and 10 (0.109 g, 0.364 mmol) in acetone (2 mL)
were stirred in a sealed tube at 90 °C for 48 h. 
N-(2,3-Bis((9Z)-octadecenyloxy)propyl)-N,N-dimethyl-13-oxo-3,6,9,12-tetraoxaicosan-1-aminium bromide OC-DODEG4.
A solution of the amine 4 2 (0.188 g, 0.303 mmol) and 11 (0.172 g, 0.449 mmol) in acetone (2 mL)
were stirred in a sealed tube at 90 °C for 48 h. 180 g, 56%) . RF 0.59 (CH2Cl2/MeOH, 9:1); nmax(neat)/cm 
Formation of disulfide bonds via iodine oxidation:
To the resin-bound, fully protected linear peptide was added I2 (10 eq.) in DMF (3 mL). The reaction syringe was agitated for 2 h at room temperature.
The iodine solution was drained from the syringe under vacuum and the resin washed with DMF (5 x 1.5 mL), 2% ascorbic acid in DMF (2 x 1.5 mL) and DMF (5 x 1.5 mL). The N-terminal Fmoc group was removed (as described) and the peptide cleaved from the resin.
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Peptide Cleavage: TFA/TIPS/EDT/H2O (94:2.5:2.5:1; 3 mL) was added to the reaction syringe. The syringe was then agitated for 3 h at room temperature. The cleavage cocktail was drained from the vessel under vacuum and diethyl ether (~10-15 mL) added to the filtrate. The resulting precipitate in solution was spun at 4000 rpm for 10 mins at 4 °C to produce a crude peptide pellet. The supernatant (diethyl ether) was decanted off and the peptide washed a further three times with diethyl ether. The crude peptide pellet was then re-dissolved in minimum water and freeze-dried for storage prior to purification.
Formation of disulfide bonds via aerial oxidation:
Crude peptides were re-dissolved in water (1 mg per 10 mL) and stirred at room temperature for 5 days. The solution was then concentrated and freeze-dried for storage prior to HPLC purification.
General peptide purification:
The peptides were analyzed and purified via reverse phase HPLC using a Varian ProStar system with a Model 210 solvent delivery module and a Model 320 UV detector. The purified peptide was analyzed by analytical HPLC using an Onyx monolithic C18 column (Phenomenex ® ; 100 x 3.0 mm, 2 μm macropore size, 13 nm mesopore size, flow rate 0.85 mL/min).
The analysis of the chromatograms was conducted using Star Chromatography Workstation software Version 1.9.3.2.
ESI-MS analysis was performed on a Waters Acquity Ultra Performance LC/MS machine.
HPLC Methods:
Preparative high performance liquid chromatography:
Discovery®BIO Wide Pore C18 (Varian; 100 x 21.2 mm, 5 μm beads) flow rate of 10 mL/min, and UV detection at 215 and 254 nm. Linear gradient: 10-50% B over 25 min, A = H2O, 0.1% TFA, B = CH3CN, 0.1% TFA).
Analytical high performance liquid chromatography:
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Onyx monolithic C18 column (Phenomenex ® ; 100 x 3.0 mm, 2μm macropore size, 13nm mesopore size), flow rate 0.85 mL/min, UV detection at 215nm. Linear gradient: 5-90% B over 20 min, A = H2O, 0.1% TFA, B = CH3CN, 0.1% TFA). RT 6.43 min. 
Lipid transesterification studies
The rate of DODEG4 esterification (dichain to trichain) was measured qualitatively by LC-MS (Waters Acquity LC SQD; Column: C18 BEH, 1.9 microns, 50 mm × 2.1 mm). Lipid vesicles, either alone or at a 1:1 molar ratio with DOPE, were prepared as described below using the thin lipid film method (but with bath sonication for 10 min) in HPLC-grade water at pH 7.56 (at 22.3 °C) and pH 4.53 (at 22.1 °C), the latter by careful addition of 1 M HCl to unbuffered HPLC-grade water. Final concentrations of lipid were 1 mg/mL. Solutions were stored at room temperature for the duration of the experiment.
For sample analysis, lipid solutions were diluted to a concentration on 0.1 mg/mL in the relevant aqueous solvent.
Single ion monitoring experiments (Injection volume: 10 µL; Gradient: 5-95% MeCN over 4 min then held at 95% MeCN for 30 s; Flow rate: 0.6 mL/min) of 2 and 4 ions were performed respectively for DODEG4 and DODEG4/DOPE solutions. Mass spectra were obtained by summing the scans across the detected peak.
Transfection procedures and biophysical studies Preparation of vesicles
Cationic di-chain and tri-chain lipids were formulated into vesicles at a 1:1 molar ratio with DOPE (and in some instances lysoPE) and a final cationic lipid concentration of 1 mg/mL (or 2 mg/mL for neutron scattering experiments). The required amount of lipids was weighed into a vial and dissolved in chloroform, and the solvent evaporated in vacuo overnight to produce a thin lipid film.
The film was then hydrated with the required amount of water (D2O was used for neutron scattering experiments). The resulting vesicle suspension was then probe sonicated for 5 min using a LucasDawes probe sonicator (model: 7535A) operating at 50% maximum output. The vesicles were then centrifuged at 13,000 rpm (~16,000 g) for 5 min to remove any titanium particles shed from the probe.
Formulation of lipopolyplexes
Unless otherwise stated, lipid:peptide:DNA (LPD) complexes were prepared at 0.25:6.5:1 charge ratios. This was equivalent to approximately 0.75-1:4:1 LPD weight ratios. Previous studies showed that the order of mixing of the three components was crucial for the activity of the complex. The highest transfection efficiency was obtained when peptide was added to the lipid first, at equal volumes to each other, followed by the addition of and an equal volume of DNA to the lipid:peptide S34 mixture at the intended concentrations. 8 For example, 50 µL of 0.08 mg/mL peptide was added to 50 µL containing 0.75-1 µg of lipid, then 100 µL of 0.1 mg/mL DNA was added to the lipid:peptide mixture.
Dynamic light scattering
1 mL samples of vesicles or PD and LPD complexes, using gWIZ luciferase plasmid (pDNA), were prepared and transferred to a plastic clear-sided cuvette. Size and zeta potential of the complexes were measured by dynamic light scattering using a Zetasizer Nano-ZS series, Malvern Instruments Ltd, UK.
Cell culture
Rat All measurements were carried out in triplicate, and the error bars represent the standard deviation calculated from three different measurements carried out in one experiment.
Gel retardation, release and protection assay
The binding, release and protection of pDNA from DNAse I degradation that the LPD complexes afforded was determined using agarose gel electrophoresis. LPD complexes were prepared at a final pDNA concentration of 0.25 µg per 10 µL per well at 0.25:6.5:1 LPD charge ratios. To determine pDNA binding efficiency, 10 µL of the LPD complex without further treatment was loaded into the first well. To measure the degradation of the pDNA in the complex, 0.5 µL of 0.1 M MgCl2 was added to a 10 µL LPD sample followed by the addition of 0.5 µL of either 500 or 1000 U/mL of DNAse I. The samples were incubated at 37 °C for 10 minutes after which the reaction was stopped by the addition of 1.5 µL of 0.5 M EDTA solution. Finally, 0.4 µL of highly anionic poly-aspartic acid (pAsp) at 10 mg/mL was added to release any protected pDNA and visualise it on the gel. As a control to test the extent of pDNA release from the complex in the presence of pAsp, and the absence of DNAse I, 0.4 µL of 10 mg/mL pAsp was added to 10 µL of the LPD sample. Free pDNA and pDNA treated with DNase I were used as controls. To all the samples 2 µL of loading buffer was added before loading into wells in a 0.8% w/v agarose gel containing GelRed in tris-acetate-edetate (TAE) buffer at pH 7.4
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and run at 80 mV for one hour. The gel was visualized using a Herolab EASY UV transilluminator. The intensity of the pDNA bands were analysed using GelAnalyzer program.
Transmission electron microscopy
LPD complexes were prepared at 0.25:6.5:1 charge ratios at a final volume of 50 µL and a final pDNA concentration of 0.02 mg/mL. A drop of sample was placed on a Formavar 200 mesh copper grid for a few minutes, after which the sample was dried using a filter paper. The sample was stained by placing the grid sample face down onto a drop of 4% uranyl acetate solution for several minutes.
The grid was then washed in ethanol and water and left to dry before visualisation on an FEI Tecnai T12 transmission electron microscope, USA.
Small angle neutron scattering
Small angle neutron scattering (SANS) measurements on the parent lipid dispersions in water and on the LPD complexes were performed using the beam line, LoQ, at the ISIS pulsed neutron source (STFC Rutherford-Appleton Laboratory, Didcot, U.K). All samples were freshly made using deuterium oxide (D2O). Lipid vesicles were measured at 1 mg/mL of cationic lipid (approximating to 1.6-2 mg/mL of total lipid depending upon the molecular weight of the cationic lipid) whereas LPD complexes were formulated so that the final DNA concentration was generally 0.0625 mg/mL.
The complexes were formulated at 0.25:6.5:1 charge ratio with both peptide A and K16 and calf thymus DNA (ctDNA) instead of pDNA. In addition, several LPDs prepared using either K16 or peptide A were also investigated at a final ctDNA concentration of 0.15 mg/mL. Previous similar SANS studies showed no difference in the complex structure when ctDNA or pDNA were used. 8 Samples were placed in clean, disc-shaped fused silica cells of 2 mm path length and measured at 25 °C. The SANS intensity, I(Q), of the LPDs and vesicles as a function of the scattering vector, Q = (4π/λ)sin(θ/2), where θ/2 is the scattering angle, was determined by normalising the scattering to the appropriate sample transmission after subtraction of the scattering from the relevant solvent also normalised to its corresponding transmission. The fitting of the SANS data always included flat background corrections to allow for any mismatch in the incoherent and inelastic scattering between the sample and the solvent, with the levels of the fitted background being checked to ensure that they were physically reasonable. The SANS data for the DOTMA:DOPE vesicles and LPR complexes dispersed in D2O were routinely modeled either assuming a mixture of (isolated/single) infinite planar (lamellar)
sheets with or without one-dimensional paracrystals (stacks) to account for the presence in the sample of any multilamellar vesicles. When modeling the vesicles and LPR complexes dispersed in D2O as (single) lamellar sheets, the fits to the SANS data were obtained by the least-squares S37 refinement of three parameters, namely L, Rσ, and the absolute scale factor (together with the background, as described above), where Rσ is the Lorentz correction factor which provides information about the extent of rigidity/curvature of the lamellar sheets. In this study the polydispersity on the thickness of the bilayer (σ(L)/L) was fixed at 10-6. When stacks were added to the (single) lamellar sheet model, the fit to the SANS data was obtained by least-squares refinement of seven parameters, namely, the mean bilayer thickness (L), the Lorentz factor (Rσ), the number of 300. In addition, when modeling the SANS data using a mixed population of sheets and stacks, L, σ(L)/L, and Rσ were constrained to be the same for the isolated/single and stacked lamellae, a not unreasonable assumption. If no Bragg peak was seen in the SANS data, it was fitted using a stack with a maximum of 2 bilayers. In such cases the data was fitted using a higher number of bilayers comprising the stacks to ensure that it did not improve the quality of the fit obtained. For all models, the least-squares refinements were performed using the model-fitting routines provided in the FISH 9 software.
Circular dichroism
The circular dichroism (CD) spectra of LPD complexes prepared in D2O (used because of its better optical transparency than H2O) was measured using a Chirascan Plus spectrophotometer (Applied Appropriate D2O background subtraction was performed for all spectra. The spectra of free ctDNA, lipid vesicles alone, and peptides alone were also obtained as a reference.
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Figures: Supplementary information Figure S1 . Formation of TC-DODEG4 and lyso-PE (1 and 2) from DODEG4 and DOPE at pH 7.5, monitored by LC-MS. 
